Current Drug Targets

ISSN: 1389-4501

Current Drug Targets
Volume 11, Number 3, March 2010

Contents

Structure-Based Virtual Screening
Guest Editor: Walter Filgueira De Azevedo Jr.


Editorial Pp. 261-263


Computational Methods for De Novo Protein Design and its Applications to the Human Immunodeficiency Virus 1, Purine Nucleoside Phosphorylase, Ubiquitin Specific Protease 7, and Histone Demethylases Pp.264-278
M.L. Bellows and C.A. Floudas
[Abstract] [Purchase Article]


CDK Inhibitors: From the Bench to Clinical Trials Pp. 279-290
F. Rizzolio, T. Tuccinardi, I. Caligiuri, C. Lucchetti and A. Giordano
[Abstract] [Purchase Article]


Cyclin-Dependent Kinase Inhibitors as Anticancer Drugs Pp.291-302
V. Kryštof and S. Uldrijan
[Abstract] [Purchase Article]


Halogen Atoms in the Modern Medicinal Chemistry: Hints for the Drug Design Pp. 303-314
M.Z. Hernandes, S.M.T. Cavalcanti, D.R.M. Moreira, W.F. de Azevedo Jr. and A.C.L. Leite
[Abstract] [Purchase Article]


Advances in the Structure-Based Design of the Influenza A Neuraminidase Inhibitors Pp. 315-326
P.M. Mitrasinovic
[Abstract] [Purchase Article]


MolDock Applied to Structure-Based Virtual Screening Pp. 327-334
W.F. De Azevedo Jr.
[Abstract] [Purchase Article]


Z-DNA Binding Proteins as Targets for Structure-Based Virtual Screening Pp. 335-344
D. Kim, Y.-H. Lee, H.-Y. Hwang, K.K. Kim and H.-J. Park
[Abstract] [Purchase Article]


General Articles

Future Prospect of RNA Interference for Cancer Therapies Pp. 345-360
E. Ashihara, E. Kawata and T. Maekawa
[Abstract] [Purchase Article]


Valproic Acid in the Complex Therapy of Malignant Tumors Pp. 361-379
J. Hrebackova, J. Hrabeta and T. Eckschlager
[Abstract] [Purchase Article]


Advances in Antiplatelet Therapy for Stroke Prevention: the New P2Y12 antagonists Pp. 380-391
A. Giossi, A. Pezzini, E.D. Zotto, I. Volonghi, P. Costa, D. Ferrari and A. Padovani
[Abstract] [Purchase Article]




Abstracts


[Back to top] [Purchase Article]
Computational Methods for De Novo Protein Design and its Applications to the Human Immunodeficiency Virus 1, Purine Nucleoside Phosphorylase, Ubiquitin Specific Protease 7, and Histone Demethylases
M.L. Bellows and C.A. Floudas

This paper provides an overview of computational de novo protein design methods, highlighting recent advances and successes. Four protein systems are described that are important targets for drug design: human immunodeficiency virus 1, purine nucleoside phosphorylase, ubiquitin specific protease 7, and histone demethylases. Target areas for drug design for each protein are described, along with known inhibitors, focusing on peptidic inhibitors, but also describing some small-molecule inhibitors. Computational design methods that have been employed in elucidating these inhibitors for each protein are outlined, along with steps that can be taken in order to apply computational protein design to a system that has mainly used experimental methods to date.


[Back to top] [Purchase Article]
CDK Inhibitors: From the Bench to Clinical Trials
F. Rizzolio, T. Tuccinardi, I. Caligiuri, C. Lucchetti and A. Giordano

Cell cycle deregulation is one of the first steps that transform normal cells into tumor cells. CDKs are a family of proteins devoted to controlling cell cycle entry, progression and exit. Studies from animal models show a tissue-specific essentiality of the single CDKs. In cancer cells, mis-regulation of CDK function is a common event. For this reason the pioneer compound Flavopiridol was developed and many new drugs are currently under development. ATP and the last generation of non-ATP competitive inhibitors are now emerging as one of the most potentially powerful target therapies. Many clinical trials are ongoing, as either a single agent or in combination with the classical cytotoxic agents. In this review, we discuss new strategies and methods to design more potent, selective and specific CDK inhibitors, starting from evidence emerging from animal and cancer cell models.


[Back to top] [Purchase Article]
Cyclin-Dependent Kinase Inhibitors as Anticancer Drugs
V. Kryštof and S. Uldrijan

Poor therapeutic outcomes and serious side effects, together with acquired resistance to multiple drugs, are common problems of current cancer therapies. Therefore, there is an urgent need for new cancer-targeted drugs, which has led (inter alia) to the development of molecules that can specifically inhibit cyclin-dependent kinases (CDKs). In addition to their cell cycle regulatory functions, CDKs, especially CDK7 and CDK9, play important roles in the regulation of RNA polymerase II-mediated transcription. Here, we report on progress in the preclinical development of CDK inhibitors and their anticancer activities. Special attention is paid to the action mechanisms of the pan-specific CDK inhibitors flavopiridol and roscovitine, which have already entered phase II clinical trials as treatments for various tumours. The links between their ability to inhibit transcription and sensitisation of some types of cancer to apoptosis, mechanisms leading to p53 activation, and their synergistic cooperation with common DNA damaging drugs are also discussed. It has been demonstrated that drug-resistant cancer cells can arise during therapeutic application of small molecule protein kinase inhibitors. Clinical resistance to CDK inhibitors has not yet been described, but by comparing CDKs to other kinases, and CDK inhibitors to other clinically used protein kinase inhibitors, we also discuss possible mechanisms that could lead to resistance to CDK inhibitors.


[Back to top] [Purchase Article]
Halogen Atoms in the Modern Medicinal Chemistry: Hints for the Drug Design
M.Z. Hernandes, S.M.T. Cavalcanti, D.R.M. Moreira, W.F. de Azevedo Jr. and A.C.L. Leite

A significant number of drugs and drug candidates in clinical development are halogenated structures. For a long time, insertion of halogen atoms on hit or lead compounds was predominantly performed to exploit their steric effects, through the ability of these bulk atoms to occupy the binding site of molecular targets. However, halogens in drug – target complexes influence several processes rather than steric aspects alone. For example, the formation of halogen bonds in ligand-target complexes is now recognized as a kind of intermolecular interaction that favorably contributes to the stability of protein-ligand complexes. This paper is aimed at introducing the fascinating versatility of halogen atoms. It starts summarizing the prevalence of halogenated drugs and their structural and pharmacological features. Next, we discuss the identification and prediction of halogen bonds in protein–ligand complexes, and how these bonds should be exploited. Interesting results of halogen insertions during the processes of hit-to-lead or lead-to-drug conversions are also detailed. Polyhalogenated anesthetics and protein kinase inhibitors that bear halogens are analyzed as cases studies. Thereby, this review serves as a guide for the virtual screening of libraries containing halogenated compounds and may be a source of inspiration for the medicinal chemists.


[Back to top] [Purchase Article]
Advances in the Structure-Based Design of the Influenza A Neuraminidase Inhibitors
P.M. Mitrasinovic

Since 2003, highly pathogenic H5N1 influenza viruses have been the cause of large-scale death in poultry and the subsequent infection and death of over 140 humans. At present, there are only three licensed anti-Influenza drugs namely Relenza (Zanamivir - ZMV), Tamiflu (Oseltamivir - OTV) and Amantadine/Rimantadine. The latter targets the M2 ion channel whereas the other compounds target neuraminidase (NA) and were designed through structure-based enzyme inhibitor programmes. Some structural knowledge of the Influenza neuraminidase is now known, due to remarkable advances in crystallographic techniques. The structure of H5N1 NA is particularly attractive because it offers new opportunities for drug design. Besides a profound impact that structural biology has had on understanding the Influenza virus and the rational design of antivirals, computational methods are now a viable partner to experiment in designing NA inhibitors. We herein discuss the development of current neuraminidase inhibitors, the emergence of resistance to them and recent research progress towards the development of new inhibitors.


[Back to top] [Purchase Article]
MolDock Applied to Structure-Based Virtual Screening
W.F. De Azevedo Jr.

Molecular docking is a simulation process where the binding of a small molecule is identified in the structure of a protein target. There are several different computational approaches to solve this problem. Here it is described recent developments in application of evolutionary algorithms to molecular docking simulations. Evolutionary algorithms are classified as a group of computational techniques based on the concepts of Darwin’s theory of evolution that are designed to find the best possible solution to optimization problems. A successfully implementation of this algorithm can be found in the program MolDock. The main features of MolDock are reviewed here. We also describe application of MolDock to purine nucleoside phosphorylase, shikimate kinase and cyclin-dependent kinase 2.


[Back to top] [Purchase Article]
Z-DNA Binding Proteins as Targets for Structure-Based Virtual Screening
D. Kim, Y.-H. Lee, H.-Y. Hwang, K.K. Kim and H.-J. Park

Z-DNA, the alternative form of double-stranded DNA involved in a variety of nucleotide metabolism, is recognized and stabilized by specific Z-DNA binding proteins (ZBPs). Three ZBPs known in vertebrates --ADAR1, DAI and PKZ-- modulate innate immunity, particularly, the IFN-induced immune response. The E3L protein of vaccinia virus appears to compete with the host ZBP for Z-DNA binding, thereby suppressing the host immune system. ZBPs are, therefore, considered to be attractive therapeutic targets for infectious and immune diseases. Recent advances in computer-aided drug development combined with the high-resolution crystal and NMR structures of ZBPs have enabled us to discover novel candidates for ZBP inhibitors. In this study, we present an overview of Z-DNA and known ZBPs as drug targets, and summarize recent progress in the structure-based identification of ZBP inhibitors.


[Back to top] [Purchase Article]
Future Prospect of RNA Interference for Cancer Therapies
E. Ashihara, E. Kawata and T. Maekawa

RNA interference (RNAi) is a phenomenon of sequence-specific gene silencing in mammalian cells and its discovery has lead to its wide application as a powerful tool in post-genomic research. Recently, short interfering RNA (siRNA), which induces RNAi, has been experimentally introduced as a cancer therapy and is expected to be developed as a nucleic acid-based medicine.

Selection of appropriate gene targets is an important parameter in the potential success of siRNA cancer therapies. Candidate targets include genes associated with cell proliferation, metastasis, angiogenesis, and drug resistance. Importantly, silencing of such genes must not affect the functions of normal cells. Development of suitable drug delivery systems (DDSs) is also an important issue. Numerous methods to transfect siRNAs into cells have been developed, and the use of non-viral DDSs is preferred because it offers greater safety for clinical application than does the use of viral DDSs. Currently, atelocollagen and cationic liposomes represent the most advantageous non-viral DDSs available.

In this article, we briefly review the mechanism of RNAi and non-viral DDSs. Next we discuss in detail some of the most recent findings concerning the administration of potential nucleic acid-based drugs against polo-like kinase-1 (PLK-1), which regulates the mitotic process in mammalian cells. These promising results demonstrate that PLK-1 is a suitable target for cancer therapy. Finally, several current clinical trials of RNAi therapies against cancers are discussed. Results of current studies and clinical trials demonstrate that manipulation of RNAi mechanism by use of targeted siRNA offers promising strategies for cancer therapie.


[Back to top] [Purchase Article]
Valproic Acid in the Complex Therapy of Malignant Tumors
J. Hrebackova, J. Hrabeta and T. Eckschlager

Valproic acid (VPA) has been used for epilepsy treatment since the 1970s. Recently, it was demonstrated that it inhibits histone deacetylases (HDAC), modulates cell cycle, induces tumor cell death and inhibits angiogenesis in various tumor models. The exact anticancer mechanisms of VPA remains unclear, but HDAC inhibition, extracellular-regulated kinase activation, protein kinase C inhibition, Wnt-signaling activation, proteasomal degradation of HDAC, possible downregulation of telomerase activity and DNA demethylation participate in its anticancer effect. Hyperacetylation of histones, as a result of HDAC inhibition, seems to be the most important mechanism of VPA´s antitumor action.

Preclinical data suggest that the anticancer effect of chemotherapy is augmented when VPA is used in combination with cytostatics. Besides the effects of pretreatment with HDAC inhibitors, which increases the efficiency of 5-aza-2´-deoxycytidine, VP-16, ellipticine, doxorubicin and cisplatin, pre-exposure to VPA increases the cytotoxicity of topoisomerase II inhibitors. There are two suggested cell death mechanisms caused by potentiation of anticancer drugs by HDAC inhibitors that are neither exclusive nor synergistic. The first involves apoptosis and can be both p53 dependent or independent; the second involves mechanisms other than apoptosis. In resistant chronic myeloid leukemia (CML), VPA restores sensitivity to imatinib. We have demonstrated the synergistic effects of VPA and cisplatin in neuroblastoma cells.

VPA can be taken orally, crosses the blood brain barrier and can be used for extended periods. Clinical trials in patients with malignancies are being conducted. The use of VPA prior to or together with anticancer drugs may thus prove a beneficial treatment.


[Back to top] [Purchase Article]
Advances in Antiplatelet Therapy for Stroke Prevention: the New P2Y12 antagonists
A. Giossi, A. Pezzini, E.D. Zotto, I. Volonghi, P. Costa, D. Ferrari and A. Padovani

Thrombus formation at a site of arterial injury (eg, rupture of an atherosclerotic plaque in a carotid artery), a crucial step in the pathogenesis of cerebral ischemia, is initiated by the adhesion of platelets to the arterial wall. In vivo, activated platelets release adenosine diphosphate (ADP), whose binding to the platelet P2Y12 receptor elicits progressive and sustained platelet aggregation. As a result, this receptor has been a target for the development of clinically effective antiplatelet agents, such as the thienopyridines ticlopidine and, more recently, clopidogrel, the only two currently FDA-approved P2Y12 antagonists. Clopidogrel has a well-established role as an antithrombotic agent in the setting of ischemic stroke. However, several challenges remain, including the relatively slow onset of action of this drug and the phenomenon of clopidogrel response variability or “resistance”. A number of novel P2Y12 antagonists are therefore under investigation to determine whether they can result in better or more rapid antithrombotic effects than clopidogrel, without an unacceptable increase in hemorrhagic (or other) side effects. These include 1) prasugrel, an orally-administered thienopyridine prodrug, 2) ticagrelor (AZD6140), an ATP analog reversible P2Y12 antagonist, 3) cangrelor, an intravenously-administered reversible P2Y12 antagonist, and 4) PRT060128. Whether the promising pharmacological profile of these drugs will be translated into clinical benefit for stroke patients will be determined by the results of clinical trials.